Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study

Wyles David; Brau Norbert; Kottilil Shyam; Daar Eric S.; Ruane Peter; Workowski Kimberly; Luetkemeyer Anne; Adeyemi Oluwatoyin; Kim Arthur Y.; Doehle Brian; Huang K. C.; Mogalian Erik; Osinusi Anu; McNally John; Brainard Diana M.; McHutchison John G.; Naggie Susanna; Sulkowski Mark

首页> 外文期刊>Clinical infectious diseases >Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study

【24h】

Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study

机译：Sofosbuvir和Velpatasvir用于治疗患有人免疫缺陷病毒的患者乙型肝炎病毒1型：开放标签，第3期研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background. A safe, simple, effective, and pan-genotypic regimen to treat hepatitis C virus (HCV) infection in patients coinfected with human immunodeficiency virus type 1 (HIV-1) remains a medical need. We assessed the efficacy and safety of the NS5B polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir for HCV in patients coinfected with HIV-1.

机译：背景。在与人免疫缺陷病毒1型（HIV-1）携带的患者中治疗丙型肝炎病毒（HCV）感染的安全，简单，有效和泛基因型方案仍然是医疗需求。我们评估了HIV-1患者中NS5B聚合酶抑制剂Sofosbuvir和NS5A抑制剂Velpatasvir的疗效和安全性。

著录项

来源
《Clinical infectious diseases》 |2017年第1期|共7页
作者
Wyles David; Brau Norbert; Kottilil Shyam; Daar Eric S.; Ruane Peter; Workowski Kimberly; Luetkemeyer Anne; Adeyemi Oluwatoyin; Kim Arthur Y.; Doehle Brian; Huang K. C.; Mogalian Erik; Osinusi Anu; McNally John; Brainard Diana M.; McHutchison John G.; Naggie Susanna; Sulkowski Mark;
展开▼
作者单位

Denver Hlth &

Hosp Author Div Infect Dis Denver CO USA;

James J Peters Vet Affairs Med Ctr Bronx NY USA;

Univ Maryland Inst Human Virol Baltimore MD 21201 USA;

Harbor UCLA Med Ctr Los Angeles Biomed Res Inst Torrance CA 90509 USA;

Ruane Med &

Liver Hlth Inst Los Angeles CA USA;

Emory Univ Atlanta GA 30322 USA;

Univ Calif San Francisco San Francisco CA 94143 USA;

Cook Cty Hlth &

Hosp Syst CORE Ctr Chicago IL USA;

Massachusetts Gen Hosp Boston MA 02114 USA;

Gilead Sci Foster City CA USA;

Gilead Sci Foster City CA USA;

Gilead Sci Foster City CA USA;

Gilead Sci Foster City CA USA;

Gilead Sci Foster City CA USA;

Gilead Sci Foster City CA USA;

Gilead Sci Foster City CA USA;

Duke Univ Durham NC USA;

Johns Hopkins Univ Sch Med Baltimore MD USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类传染病;
关键词
ASTRAL-5; HCV-HIV coinfection; hepatitis C virus; sofosbuvir; velpatasvir;

机译：星式-5;HCV-HIV繁殖;丙型肝炎病毒;Sofosbuvir;Velpatasvir;

相似文献

外文文献
中文文献
专利

1. Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study [J] . Wyles David, Brau Norbert, Kottilil Shyam, Clinical infectious diseases . 2017,第1期

机译：Sofosbuvir和Velpatasvir用于治疗患有人免疫缺陷病毒的患者乙型肝炎病毒1型：开放标签，第3期研究
2. Sofosbuvir, Simeprevir, and Ribavirin for the Treatment of Hepatitis C Virus Recurrence in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Liver Transplant Recipients [J] . Campos-Varela Isabel, Straley Stephanie, Agudelo Eliana Z., Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society . 2015,第2期

机译：Sofosbuvir，Simeprevir和Ribavirin在人类免疫缺陷病毒/丙型肝炎病毒合并感染的肝移植受者中治疗丙型肝炎病毒复发的治疗
3. The Sofosbuvir (SOF) and Velpatasvir (VEL) Regimen is Associated with High Efficacy and Improvement of Patient-Reported Outcomes (PROs) in Patients Co-infected with Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV): The Data from ASTRAL-5 [J] . Younossi Zobair M., Stepanova Maria, Sulkowski Mark S., Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：Sofosbuvir（SOF）和VelpataSvir（VelpataSvir（velpataSvir（velpatasvir（velpatasvir（velpatasvir）与患者报告的患者报告的患者的高效性和改善有关，患者患者与丙型肝炎病毒（HCV）和人类免疫缺陷病毒（HIV）（HIV）：来自星式的数据 -5
4. Simultaneous extraction of human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) RNA with the M1000 apparatus does not impair the measurement of the viral load of both viruses when tested by using the LCx PCR system [C] . T. Bourlet, S. Thamm, S. Pillet, European Congress of Virology . 2004

机译：通过使用LCX PCR系统测试，同时提取人免疫缺陷病毒类型1（HIV-1）和丙型肝炎病毒（HCV）RNA，不会损害两种病毒的病毒载量的测量
5. Hepatitis C virus (HCV) replication in vitro and the effect of HCV on human immunodeficiency virus (HIV-1) coreceptor usage and diversity in the coinfected patient. [D] . Franco, Kelly Flory. 2007

机译：丙型肝炎病毒（HCV）的体外复制以及HCV对合并感染患者中人免疫缺陷病毒（HIV-1）共受体使用和多样性的影响。
6. Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label Phase 3 Study [O] . David Wyles, Norbert Bräu, Shyam Kottilil, -1

机译：Sofosbuvir和Velpatasvir用于治疗人类免疫缺陷病毒1型共感染患者的丙型肝炎病毒：一项开放标签的3期研究
7. Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study [O] . David Wyles, Norbert Bräu, Shyam Kottilil, 2017

机译：Sofosbuvir和Velpatasvir用于治疗与人免疫缺陷病毒1型患者患者的丙型肝炎病毒：开放标签，第3期研究

Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study

摘要

著录项

相似文献

相关主题

期刊订阅